CD8A and neoplasm: Compared with anti-PD-1 monotherapy, cNP combined with anti-PD-1 therapy synergistically inhibited tumor growth, prolonged survival, and significantly increased the proportion of CD8<sup>+</sup> T cells and CD19<sup>+</sup> B cells, while simultaneously inhibiting the infiltration levels of Treg cells and M-MDSCs, and promoting macrophage polarization from M2 to M1 types, significantly alleviating the immunosuppressive state of TME.